Cornercap Investment Counsel Inc. Sells 781 Shares of Hologic, Inc. (NASDAQ:HOLX)

Cornercap Investment Counsel Inc. cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,409 shares of the medical equipment provider’s stock after selling 781 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Hologic were worth $1,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of HOLX. Brooklyn Investment Group grew its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 145 shares during the period. Smartleaf Asset Management LLC raised its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the period. Trivant Custom Portfolio Group LLC raised its stake in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after buying an additional 169 shares during the period. Loomis Sayles & Co. L P lifted its position in shares of Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 183 shares in the last quarter. Finally, UMB Bank n.a. raised its stake in Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 188 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 1.6 %

Shares of Hologic stock opened at $61.32 on Friday. The firm’s 50 day moving average price is $65.24 and its 200-day moving average price is $73.35. The company has a market cap of $13.76 billion, a P/E ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley decreased their target price on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Evercore ISI reduced their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research report on Thursday, February 6th. Finally, Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Hologic currently has an average rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.